Retinopathy Of Prematurity (Ophthalmology) Drugs Pipeline Report 2021

Retinopathy Of Prematurity (Ophthalmology) Drugs Pipeline Report 2021

[ad_1]

DUBLIN, September 09, 2021–(BUSINESS WIRE)–The “Retinopathy Of Prematurity (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

The report provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

Retinopathy Of Prematurity – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).

  • The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Key Topics Covered:

Introduction

Retinopathy Of Prematurity – Overview

Pipeline Overview

  • Pipeline by Companies

  • Pipeline by Universities/Institutes

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

Retinopathy Of Prematurity – Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Retinopathy Of Prematurity – Companies Involved in Therapeutics Development

  • Advanced Imaging Projects Inc

  • Anida Pharma Inc

  • AntlerA Therapeutics Inc

  • Ayuvis Research Inc

  • D. Western Therapeutics Institute Inc

  • Drive Therapeutics LLC

  • Everglades Biopharma LLC

  • Insmed Inc

  • Kowa Co Ltd

  • Novelty Nobility Inc

  • Orphanix GmbH

  • Pamdeca LLC

  • Recordati Rare Diseases Inc

  • Regeneron Pharmaceuticals Inc

  • Signablok Inc

  • Worphmed Srl

Retinopathy Of Prematurity – Drug Profiles

  • aflibercept

  • AVR-123

  • D-2P014

  • mecasermin rinfabate

  • melatonin

  • Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications

  • Monoclonal Antibody to Agonize Frizzled receptor 4 and LRP5 for Diabetic Retinopathy and Retinopathy of Prematurit

  • Neuroprotectin D1

  • NN-2901

  • PMD-336

  • Propranolol hydrochloride

  • ripasudil

  • Small Molecule for Retinopathy of Prematurity

  • Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis, Retinopathy Of Prematurity and Hemorrhagic Shock

  • vitamin A palmitate

Retinopathy Of Prematurity – Dormant Projects

Retinopathy Of Prematurity – Product Development Milestones

Featured News & Press Releases

  • Mar 11, 2019: Bascom Palmer’s Dr. Wei Li awarded $9.12 million NEI grant

  • Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants

  • Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ftwrqk

View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005664/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

[ad_2]

Source link